Active, not recruitingPhase 3NCT06295692
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Studying DITRA
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Janssen Pharmaceutical K.K.
- Principal Investigator
- Janssen Pharmaceutical K.K., Japan Clinical TrialJanssen Pharmaceutical K.K.
- Intervention
- JNJ-77242113(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2024 – 2027
Study locations (12)
- JR Sapporo Hospital, Hokkaido, Japan
- Ichinomiya Municipal Hospital, Ichinomiya, Japan
- Teikyo University Hospital, Itabashi Ku, Japan
- Hospital of the University of Occupational and Environmental Health, Kitakyushu-shi, Japan
- Kumamoto University Hospital, Kumamoto, Japan
- Nagoya City University Hospital, Nagoya, Japan
- Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital, Osaka, Japan
- Tohoku University Hospital, Sendai, Japan
- Dokkyo Medical University Hospital, Shimotsuga Gun, Japan
- Tokyo Medical University Hospital, Shinjuku, Japan
- Fujita Health University Hospital, Toyoake, Japan
- Mie University Hospital, Tsu, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06295692 on ClinicalTrials.govOther trials for DITRA
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07552454Picankibart in Palmoplantar PustulosisXijing Hospital
- RECRUITINGPHASE2NCT07314060A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular PsoriasisChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ACTIVE NOT RECRUITINGNCT06952465A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With PsoriasisBristol-Myers Squibb
- RECRUITINGPHASE2, PHASE3NCT06477536Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular PsoriasisShanghai Huaota Biopharmaceutical Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE1NCT06433531A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE3NCT06323356A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisTakeda
- ACTIVE NOT RECRUITINGPHASE4NCT06013969A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated FlaresBoehringer Ingelheim
- RECRUITINGNCT06100991CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness RegistryCorEvitas